Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2025.2587174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Abdullah Alrahmani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde University of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: COVID-19, Gabapentin, Practice Patterns, Physicians', Analgesics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Gabapentinoids are commonly used for neuropathic pain but are increasingly linked with misuse/mortality. In 2019, the UK reclassified them as Schedule 3 controlled drugs. The onset of the COVID-19 pandemic created additional uncertainty regarding their utilization. We aimed to examine the impact of reclassification and COVID-19 on gabapentinoid utilization and related mortality in Scotland and Northern Ireland (NI). RESEARCH DESIGN/METHODS: A population-based, cross-national study was conducted using prescribing datasets (April/2018-February/2025). Utilization was measured as total items dispensed per 1,000 inhabitants and defined daily doses per 1,000 inhabitants/day. Gabapentinoid-related mortality data were analyzed in parallel. Segmented regression assessed changes in trends following the 2019 reclassification and two COVID-19 lockdowns. RESULTS: Overall utilization was higher in Scotland than NI. In Scotland, pregabalin prescribing significantly increased over the study period, while NI demonstrated a decline, largely attributable to formulary restrictions. Neither reclassification nor pandemic lockdowns were associated with statistically significant changes in prescribing patterns. Mortality rates showed no significant correlation with utilization in either country. CONCLUSIONS: Gabapentinoid utilization does not appear to have been significantly affected by the reclassification or by COVID-19. Cross-national differences underscore the influence of formulary guidance, highlighting the need for harmonized policies/patient-level research to inform safe prescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Strathclyde University of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
- Department of Engineering, College of Engineering and Technology, University of Technology and Applied Sciences, Muscat, Oman.
- College of Pharmacy, Al-Kitab University, Kirkuk, Iraq.
- Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
- College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Zitieren
APA
Alrahmani, A., Azeez, M., Baker, S., & Kurdi, A. (2025). Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2587174
Vancouver
Alrahmani A, Azeez M, Baker S, Kurdi A. Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2587174
BibTeX
@article{Alrahmani2025,
author = {Alrahmani, Abdullah and Azeez, Mabast and Baker, Sahar and Kurdi, Amanj},
title = {Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2025.2587174}
}
EUVIMED